Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma - Concepedia

Concepedia

Publication | Closed Access

Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma

40

Citations

18

References

2021

Year

Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Ryoji Miyahara, Akira Sawaki, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yohei Miyachi, Arisa Mii,

Abstract

Early changes in AFP might be useful for predicting the antitumor efficacy of atezolizumab plus bevacizumab in patients with advanced HCC. An AFP ratio of 1.4 or higher at 3 weeks might be an early predictor of refractoriness to atezolizumab plus bevacizumab therapy.

References

	Year	Citations

Page 1